Tegafur

Tegafur
Clinical data
Other names	5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione
AHFS/Drugs.com	International Drug Names
License data	EU EMA: by INN;
Pregnancy; category	AU: D;
Routes of; administration	Oral
ATC code	L01BC03 (WHO) L01BC53 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: POM (Prescription only);
Pharmacokinetic data
Elimination half-life	3.9-11 hours
Identifiers
	IUPAC name (RS)-5-Fluoro-1-(tetrahydrofuran-2-yl)pyrimidine-2,4(1H,3H)-dione;
CAS Number	17902-23-7 ;
PubChem CID	288216;
DrugBank	DB09256 ;
ChemSpider	254191 ;
UNII	1548R74NSZ;
KEGG	D01244 ;
ChEMBL	ChEMBL20883 ;
CompTox Dashboard (EPA)	DTXSID001009966 ;
ECHA InfoCard	100.038.027
Chemical and physical data
Formula	C8H9FN2O3
Molar mass	200.169 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC=1C(=O)NC(=O)N(C=1)[C@@H]2OCCC2;
	InChI InChI=1S/C8H9FN2O3/c9-5-4-11(6-2-1-3-14-6)8(13)10-7(5)12/h4,6H,1-3H2,(H,10,12,13)/t6-/m1/s1 ; Key:WFWLQNSHRPWKFK-ZCFIWIBFSA-N ;
	(what is this?) (verify)

Tegafur is a chemotherapeutic prodrug of 5-fluorouracil (5-FU) used in the treatment of cancers. It is a component of the combination drug tegafur/uracil. When metabolised, it becomes 5-FU.

It was patented in 1967 and approved for medical use in 1972.